Diabetic encephalopathy cognitive dysfunction
Conditions
Interventions
Experimental group:Give patients Buyang Huanwu decoction
Control group:Give patients a placebo with no treatment effect patients placebo that had no therapeutic effect
Sponsors
The First Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
55 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 55 to 75 years, meeting the diagnostic criteria for T2DM established by WHO in 1999; 2. HbA1c range: 6.5-9%; 3. Comply with the standard of TCM syndrome differentiation and diagnosis; 4. Montreal Cognitive Assessment Scale (MoCA) score < 26 points, complex instrumental daily activities may be slightly impaired, normal activities of daily living, and do not meet the diagnostic criteria for dementia; 5. Able to communicate well with researchers and comply with the entire experimental requirements; 6. Exclude other factors that cause cognitive dysfunction.
Exclusion criteria
Exclusion criteria: 1. New diseases that may cause changes in blood sugar within 3 months, such as infection, myocardial infarction, tumor, inflammation, trauma and other severe stress states, as well as hyperthyroidism, hypothyroidism, hypercortisolism, acromegaly, etc.; 2. Those with cognitive impairment caused by taking drugs that increase blood sugar or improve cognition or taking neuropsychiatric drugs within 3 months. 3. Severe liver disease (including chronic persistent hepatitis, liver cirrhosis, or both positive for hepatitis B virus surface antigen and abnormal liver transaminase (serum alanine aminotransferase or aspartate aminotransferase concentration > 2.5 times the upper limit of normal); 4. History of severe renal disease or serum creatinine > 133µmol/l; 5. Known blood system disease or hemoglobin < 90 g/L (9 g/dL); 6. Hypoproteinemia, serum albumin < 35g/L; 7. Blood transfusion or blood donation within the past 3 months; 8. Severe organic diseases, including cancer, coronary heart disease, myocardial infarction or stroke, or cognitive dysfunction caused by trauma, poisoning, alcoholism, Parkinson's disease, polymyositis, etc.; 9. The evaluation of cognitive function in patients with major depression, schizophrenia and other mental diseases or delirium; 10. Infectious diseases, including tuberculosis and AIDS; and alcoholism; 11. Participated in other studies or observational investigators at the same time or within 3 months; 12. Those who cannot cooperate with the tester for various reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Montreal Cognitive Assessment Scale Score;Mini-Mental State Examination Scale Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Glycosylated albumin;Blood glucose; | — |
Countries
China
Contacts
Public ContactXu Shunjiang
The First Hospital of Hebei Medical University
Outcome results
None listed